Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1760-1767

  Bröker, Linda E ^a   De Vos, Filip Y F L ^b   Van Groeningen, Cees J ^a   Kuenen, Bart C ^a   Gall, Helen E ^a   Woo, Michael H ^c   Voi, Maurizio ^c   Gietema, Jourik A ^b   De Vries, Elisabeth G E ^b   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 275183; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ATAXIA; BILE DUCT TUMOR; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; COLON CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEART PALPITATION; HUMAN; HYPERSENSITIVITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MUSCLE FATIGUE; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PETECHIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PURPURA; RASH; SARCOMA; SENSORY NEUROPATHY; SIDE EFFECT; SKIN BRUISING; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TOXICITY; VOICE CHANGE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PAIN; TREATMENT OUTCOME;

EID: 33645677282     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2093     Document Type: Article

References (37)

1. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
2. Huizing MT, Giaccone G, van Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 1997;15:317-29.
3. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
4. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.
5. tenTije AJ, Smorenburg CH, Seynaeve C, et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004;40:352-7.
6. Belani CP, Larocca RV, Rinaldi DA, Tester WJ, Gable PS, Perry MC. A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks followed by weekly paclitaxel [abstract]. Proc Am Soc Clin Oncol 2004;23:619.
7. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC [abstract]. Proc Am Soc Clin Oncol 2004;23:6.
8. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-5.
9. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90:300-6.
10. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997;94:2031-5.
11. Malingre MM, Terwogt JM, Beijnen JH, et al. Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 2000;18:2468-75.
12. Malingre MM, Beijnen JH, Rosing H, et al. Coadministration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001;84:42-7.
13. Malingre MM, Beijnen JH, Rosing H, et al. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol 2001;47:347-54.
14. Meerum TJ, Malingre MM, Beijnen JH, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999;5:3379-84.
15. Mastalerz H, Cook D, Fairchild CR, et al. The discovery of BMS-275183: an orally efficacious novel taxane. Bioorg Med Chem 2003;11:4315-23.
16. Trump DL, Egorin MJ, Ramesh R, et al. A new oral taxane (BMS-275183): phase I trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability [abstract]. Proc Am Soc Clin Oncol 2002;21:100a.
17. Rose WC, Long BH, Fairchild CR, Lee FY, Kadow JF. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 2001;7:2016-21.
18. Division of Cancer Treatment NCI. Guidelines for reporting of adverse drug reactions. Bethesda (MD): 1998.
19. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
20. WHO Offset Publication No.48. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): 1979.
21. Clopper CJ, Pearson E. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika 1934;26:404-13.
22. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
23. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, De Angelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997;35:47-53.
24. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol 1995;6:489-94.
25. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993;15:107-15.
26. Openshaw H, Beamon K, Synold TW, et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004;10:461 -7.
27. Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003;9:5756-67.
28. Moore DH, Donnelly J, McGuire WP, et al. Limited access trial using amifostine for protection against cisplatin-and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 2003;21:4207-13.
29. Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993;11:2127-35.
30. Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994;12:241-8.
31. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20:3683-90.
32. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000;6:1255-8.
33. Mathijssen RH, de Jong FA, van Schaik RH, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004;96:1585-92.
34. Yamamoto N, Tamura T, Murakami H, et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005;23:1061-9.
35. Dees EC, Watkins PB. Role of cytochrome P450 phenotyping in cancer treatment. J Clin Oncol 2005;23:1053-5.
36. Williams C, Collingwood M, Simera I, Grafton C. Short versus long duration infusions of paclitaxel for any adenocarcinoma. Cochrane Database Syst Rev 2003;CD003911.
37. Bröker LE, Ruijter R, Voi M, et al. A phase I trial investigating a twice weekly administration of the oral taxane BMS-275183 in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 2005;24:145s.